Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP1A2 | P05177 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7768431 | 1.00 | CYP1A2 (0.39) | CYP1A2 | |
| SCHEMBL2152023 | 1.00 | CYP1A2 (0.39) | CYP1A2 | |
| SCHEMBL14720558 | 1.00 | CYP1A2 (0.39) | CYP1A2 | |
| Methane SCHEMBL27984748 | 0.98 | CYP1A2 (0.38) | CYP1A2 | |
| SCHEMBL9345337 | 0.91 | CYP1A2 (0.34) | CYP1A2 | |
| Isothiocyanate SCHEMBL6155860 | 0.88 | CYP1A2 (0.35) | CYP1A2 | |
| SCHEMBL21088951 | 0.87 | — | — | |
| SCHEMBL17634027 | 0.87 | — | — | |
| SCHEMBL56901 | 0.87 | — | — | |
| SCHEMBL4819466 | 0.87 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-108610481-B | Polythiol composition having improved long-term storage stability and optical lens using the same | SKC株式会社 | 2021-04-13 | — | — | CN | disclosed |
| CN-108610480-B | Method for producing polythiol for optical lens using metal sulfide | SKC株式会社 | 2021-03-12 | — | — | CN | disclosed |
| CN-104884509-B | Bidirectional shape memory polymer, its production method and application | 亥姆霍兹中心盖斯特哈赫特材料及海岸研究中心有限公司 | 2018-01-23 | — | — | CN | disclosed |
| EP-1409468-B9 | GUANIDINOBENZAMIDES AS MC4-R AGONISTS | NOVARTIS VACCINES & DIAGNOSTIC (US) | 2009-07-29 | — | — | EP | disclosed |
| EP-1409468-B1 | GUANIDINOBENZAMIDES AS MC4-R AGONISTS | NOVARTIS VACCINES & DIAGNOSTIC (US) | 2008-11-12 | — | — | EP | disclosed |
| CN-101173114-A | Solid formaldehyde-free pigment preparations | EVONIK DEGUSSA GMBH (DE) | 2008-05-07 | — | — | CN | disclosed |
| US-6995269-B2 | Guanidinobenzamides | CHIRON CORPORATION (US) | 2006-02-07 | — | — | US | disclosed |
| EP-1409468-A2 | GUANIDINOBENZAMIDES AS MC4-R AGONISTS | CHIRON CORPORATION (US) | 2004-04-21 | — | — | EP | disclosed |
| US-6638927-B2 | Melanocortin-4 receptor (MC4-R) agonists; treating obesity or diabetes; 4-((N-cyclohexyl-3,5-dimethyl-piperazine-1-carboximidoyl)-amino)-N-(2-(2,4 -dichlorophenyl) -ethyl)-benzamide for example | CHIRON CORPORATION | 2003-10-28 | — | — | US | disclosed |
| US-20030199499-A1 | Novel guanidinobenzamides | CHIRON CORPORATION | 2003-10-23 | — | — | US | disclosed |
| US-20020137939-A1 | Melanocortin-4 receptor (MC4-R) agonists; treating obesity or diabetes; 4-((N-cyclohexyl-3,5-dimethyl-piperazine-1-carboximidoyl)-amino)-N-(2-(2,4 -dichlorophenyl)-ethyl)-benzamide for example | CHIRON CORPORATION | 2002-09-26 | — | — | US | disclosed |
| WO-2002018327-A2 | GUANIDINOBENZAMIDES AS MC4-R AGONISTS | CHIRON CORPORATION (US) | 2002-03-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030199499-A1 | Novel guanidinobenzamides | GUCY1B2, GPR119, GUCY1B1 | CYP1A2 1021/4885 |
| US-20020137939-A1 | Melanocortin-4 receptor (MC4-R) agonists; treating obesity or diabetes; 4-((N-cyclohexyl-3,5-dimethyl-piperazine-1-carboximidoyl)-amino)-N-(2-(2,4 -dichlorophenyl)-ethyl)-benzamide for example | MC4R, MC5R, MC3R | CYP1A2 1403/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.